ACTRN12610000992000
Recruiting
未知
A prospective,randomised, controlled trial to evaluate the effect of locking plates compared with gamma nails on individuals with intertrochanteric hip fractures
Zhao Gangsheng0 sites100 target enrollmentNovember 16, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- intertrochanteric hip fractures
- Sponsor
- Zhao Gangsheng
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. primary intertrochanteric hip fracture only
- •2\. BMI\<30
- •3\. no other disease that would affect the outcome of fractrue healing
- •4\. no other previous surgical treatments
Exclusion Criteria
- •1\. BMI \> 30
- •2\. the patients that received previous other surgical treatment
- •3\. the health condition is not stable
- •4\. with other diaease that would affect bone healing, such as cancer, kidney disease needs corticosteroids
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 3
A prospective, randomized trial to compare correction of ridge contour deficiency (shrinking of the gum and bone) using OSSIX® Volumax or Fibro-Gide.Dental ridge contour deficiencyOral HealthISRCTN62683103Datum Dental65
Not yet recruiting
Not Applicable
An evaluation of the effects of the iMindTime Digital Health program on wellbeingDepressionAnxietyMental Health - AnxietyMental Health - DepressionACTRN12621000129886Federation University Australia350
Active, not recruiting
Phase 1
prospective, randomized, controlled study evaluating the effect of conversion from tacrolimus treatment to mTor inhibitor-based immunosuppression + tacrolimus to boost conversion to positive SARS-CoV-2 serology after a fourth dose of the vaccine of SARS-CoV-2 mRNA in solid organ transplant recipients who have not previously responded.Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccineMedDRA version: 21.0Level: PTClassification code 10080575Term: Solid organ transplantSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-000617-13-ESFundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)50
Active, not recruiting
Phase 1
/aType 2 Diabetes mellitusMedDRA version: 17.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-000493-19-DEDiabeteszentrum Bad Lauterberg
Not yet recruiting
Phase 3
Clinical trial ofstress and Sleep management supplementCTRI/2024/07/070701ife Synergy